TransMedics Group (TMDX) KOL Call Takeaways - Canaccord Genuity

Canaccord Genuity analyst Jason Mills reiterated a Buy rating and $79.00 price target on TransMedics Group (NASDAQ: TMDX) after hosting a KOL call with Dr. Aleem Siddique, surgical director for the Lung Transplant Program and Aortic Program at the University of Nebraska Medical Center, and user of the OCS Lung System. While there were several takeaways from the call, the one most applicable to an investing framework was that lung transplant referrals had been impacted by COVID but are now recovering.

The analyst stated "Dr. Siddique stated that his experience was that the referrals for recipients with advanced lung disease weren’t coming through during COVID, but that referrals have started to improve. Given that these patient referrals often come through visits to community pulmonologists and lung specialists, who were drawn into the ICU as frontline workers during peak COVID, the referral network breakdown makes sense. Dr. Siddique also noted that these referrals also were likely paused as physicians (and likely patients) wanted to protect these advanced lung disease patients from the hospital environment during COVID."

For an analyst ratings summary and ratings history on TransMedics Group click here. For more ratings news on TransMedics Group click here.

Shares of TransMedics Group closed at $28.16 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• New Street Research Upgrades Micron Technology (MU) to Buy